SAGE Therapeutics Stock Price, News & Analysis (NASDAQ:SAGE)

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

SAGE Therapeutics Inc (NASDAQ:SAGE) announced its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported ($3.28) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($3.32) by $0.04. The biopharmaceutical company had revenue of $0.87 million for the quarter, compared to the consensus estimate of $0.27 million. The business's revenue for the quarter was down 99.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.36) earnings per share. View SAGE Therapeutics' Earnings History.

SAGE Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for SAGE Therapeutics.

SAGE Therapeutics will be holding an earnings conference call on Tuesday, November 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

14 analysts have issued 12 month price objectives for SAGE Therapeutics' shares. Their forecasts range from $80.00 to $261.00. On average, they expect SAGE Therapeutics' stock price to reach $200.27 in the next year. This suggests a possible upside of 43.1% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics.

Headlines about SAGE stock have trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SAGE Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for SAGE Therapeutics.

Some companies that are related to SAGE Therapeutics include Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), UCB (UCBJF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Mylan (MYL), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA) and Ionis Pharmaceuticals (IONS).

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Intercept Pharmaceuticals (ICPT), AbbVie (ABBV), Twitter (TWTR), ACADIA Pharmaceuticals (ACAD), Roku (ROKU) and Sarepta Therapeutics (SRPT).

SAGE Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.04%), First American Trust FSB (0.04%), Nisa Investment Advisors LLC (0.03%), Envestnet Asset Management Inc. (0.02%), Clear Street Markets LLC (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.

SAGE stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have sold SAGE Therapeutics company stock in the last year include Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.

SAGE stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Clear Street Markets LLC, Zeke Capital Advisors LLC, Nelson Van Denburg & Campbell Wealth Management Group LLC, Envestnet Asset Management Inc., First American Trust FSB, Wealthcare Advisory Partners LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for SAGE Therapeutics.

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SAGE stock can currently be purchased for approximately $139.93.

SAGE Therapeutics has a market capitalization of $7.23 billion and generates $90.27 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($8.08) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.View Additional Information About SAGE Therapeutics.

The official website for SAGE Therapeutics is http://www.sagerx.com/.

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]